Evidence map›Paper›PMID 42218807›Full record

ArticleBiomolecules & biomedicine2026

Butyl and isobutyl ortho-coumaric acid derivatives reduce self-renewal and MGMT expression in GBM cells with stem cell-like characteristics

Luis Javier Reséndiz-Castillo, Yanet Karina Gutiérrez-Mercado, Juan Carlos Mateos-Díaz, Ahtziri Socorro Carranza-Aranda, Edwin Estefan Reza-Zaldivar, Mercedes Azucuena Hernández-Sapiéns, Alejandro Arturo Canales-Aguirre

Abstract read
In one paragraph

Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luis Javier Reséndiz-CastilloPreclinical Evaluation Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara, Jalisco, Mexico.
Yanet Karina Gutiérrez-MercadoBiotechnological Laboratory for Research and Diagnosis, Department of Clinics, University of Guadalajara, Campus Los Altos, Tepatitlán de Morelos, Jalisco, Mexico.
Juan Carlos Mateos-DíazIndustrial Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, Zapopan, Jalisco, Mexico.
Ahtziri Socorro Carranza-ArandaDepartment of Philosophical, Methodological and Instrumental Disciplines, University of Guadalajara, Health Sciences Campus, Guadalajara, Jalisco, Mexico.
Edwin Estefan Reza-ZaldivarSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Monterrey, Mexico.
Mercedes Azucuena Hernández-SapiénsSchool of Engineering and Sciences, Tecnológico de Monterrey, Monterrey Campus, Monterrey, Nuevo León, Mexico.
Alejandro Arturo Canales-AguirrePreclinical Evaluation Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara, Jalisco, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ortho-coumaric acid (o-CA) derivatives, specifically butyl, isobutyl, propyl, ethyl, and methyl-o-coumarate, have emerged as potential therapeutic agents for glioblastoma multiforme (GBM). This study investigates their effects on drug resistance, proliferation, migration, maturation, cell cycle regulation, and autophagy in stem-like glioblastoma cells (SLGCs). We evaluated the biological activity of o-CA derivatives using an in vitro GBM cell model by assessing spheroid and colony formation, cell migration, autophagy marker induction, DNA damage repair protein expression, cell cycle alterations, and the expression of stemness and differentiation markers. Treatment with o-CA derivatives, particularly butyl and isobutyl, resulted in a decreased self-renewal capacity of SLGCs, as indicated by reduced spheroid and colony formation compared to temozolomide (TMZ). Additionally, butyl o-CA impaired cell migration. Cell cycle analysis revealed an increased proportion of cells in the G0/G1 phase following treatment with butyl and isobutyl o-CA, accompanied by a reduction in the S and G2/M phases. Furthermore, we observed increased expression of the autophagy marker microtubule-associated protein 1 light-chain 3B (LC3-B) in cells treated with propyl and butyl o-CA. The expression of the drug resistance marker O6-methylguanine DNA methyltransferase (MGMT) was significantly reduced, particularly in cells treated with Butyl o-CA. Moreover, butyl o-CA-treated cells demonstrated lower expression levels of the stemness markers CD133 and Nestin, in conjunction with elevated expression of the differentiation markers GFAP and NeuN. Overall, these findings suggest that o-CA derivatives, especially butyl and Isobutyl o-CA, may effectively modulate stem-like characteristics in an in vitro GBM model.

Indexed as

Brain NeoplasmsCell Self RenewalCoumaric AcidsDNA Modification MethylasesDNA Repair EnzymesGlioblastomaNeoplastic Stem CellsTumor Suppressor ProteinsAutophagyCell CycleCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansTemozolomideCoumaric AcidsDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTemozolomideTumor Suppressor Proteins

Identifiers

PMID42218807
PMCPMC13394571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.